Met amplification and HSP90 inhibitors.
Giaccone
Giuseppe
G
National Cancer Institute, Bethesda, MD, USA. giacconeg@mail.nih.gov
Rajan
Arun
A
D017209:Apoptosis; D016227:Benzoquinones / Q000494:pharmacology*; D005784:Gene Amplification; D018841:HSP90 Heat-Shock Proteins / Q000037:antagonists & inhibitors* / Q000378:metabolism; D006801:Humans; D007211:Indoles / Q000494:pharmacology; D047029:Lactams, Macrocyclic / Q000494:pharmacology*; D010879:Piperazines / Q000494:pharmacology; D019859:Proto-Oncogene Proteins c-met / Q000037:antagonists & inhibitors / Q000235:genetics / Q000378:metabolism*; D013449:Sulfonamides / Q000494:pharmacology; D014407:Tumor Cells, Cultured
C478479:((3Z)-N-(3-chlorophenyl)-3-((3,5-dimethyl-4-((4-methylpiperazin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-N-methyl-2-oxo-2,3-dihydro-1H-indole-5-sulfonamide); D016227:Benzoquinones; D018841:HSP90 Heat-Shock Proteins; D007211:Indoles; D047029:Lactams, Macrocyclic; D010879:Piperazines; D013449:Sulfonamides; C112765:tanespimycin; D019859:Proto-Oncogene Proteins c-met